🇺🇸 FDA
Pipeline program

To evaluate the pharmacokinetics and safety of nolasiban

RPN-NLS01

Phase 1 other active

Quick answer

To evaluate the pharmacokinetics and safety of nolasiban for not applicable (submitted trial is a pharmacokinetic study in healthy subjects) is a Phase 1 program (other) at Novo mesto with 1 ClinicalTrials.gov record(s).

Program details

Company
Novo mesto
Indication
not applicable (submitted trial is a pharmacokinetic study in healthy subjects)
Phase
Phase 1
Modality
other
Status
active

Clinical trials